Merck / 默沙东

Merck / 默沙东 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as the central [[MultinationalPharmaPatentCliffAnxiety|patent-cliff anxiety]] example. The episode says [[Keytruda|K药]] became a larger PD-1 success than earlier rivals partly through clinical-development strategy, which makes its eventual patent expiration a major pipeline-replacement problem.

The source also uses Merck to show defensive BD behavior. In the episode’s telling, Merck publicly asked to see stronger overall-survival evidence around the [[PD1VEGFBispecific|PD-1/VEGF bispecific]] mechanism, but later moved to acquire a Chinese PD-1/VEGF asset.

Connections

• Keytruda / K药 - product at the center of the source’s patent-cliff and PD-1 comparison.
• Akeso / 康方生物 and PD-1/VEGF Bispecific - Chinese-asset mechanism that forced close attention.
• Multinational Pharma Patent-Cliff Anxiety and China Biotech Asset Repricing - strategy context for Merck’s source role.